Holen Sie sich die Stockscreener-App
16.78
3.13%
0.51
Schlusskurs vom Vortag:
$16.27
Offen:
$16.74
24-Stunden-Volumen:
249.74K
Relative Volume:
1.24
Marktkapitalisierung:
$558.90M
Einnahmen:
$65.42M
Nettoeinkommen (Verlust:
$-32.96M
KGV:
-13.21
EPS:
-1.27
Netto-Cashflow:
$-19.87M
1W Leistung:
+0.72%
1M Leistung:
+24.76%
6M Leistung:
+29.68%
1J Leistung:
+45.79%
1-Tages-Spanne:
$16.25
$16.94
1-Wochen-Bereich:
$16.04
$17.22
52-Wochen-Spanne:
$7.5625
$18.98
Neuropace Inc Stock (NPCE) Company Profile
Firmenname
Neuropace Inc
Sektor
Branche
Telefon
(650) 237-2700
Adresse
455 N. BERNARDO AVENUE, MOUNTAIN VIEW
Vergleichen Sie NPCE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NPCE
Neuropace Inc
|
16.78 | 541.92M | 65.42M | -32.96M | -19.87M | -1.27 |
|
ABT
Abbott Laboratories
|
122.55 | 210.84B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
92.70 | 137.17B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
353.80 | 133.55B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
100.77 | 127.71B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
83.92 | 48.33B | 5.88B | 1.34B | 799.60M | 2.3489 |
Neuropace Inc Stock (NPCE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-01-21 | Eingeleitet | UBS | Buy |
| 2024-03-14 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-01-30 | Eingeleitet | Leerink Partners | Outperform |
| 2023-11-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-08-24 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2023-02-22 | Eingeleitet | Lake Street | Buy |
| 2022-04-06 | Eingeleitet | Wolfe Research | Outperform |
| 2022-01-19 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-01-07 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-11 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-08-18 | Eingeleitet | Robert W. Baird | Outperform |
| 2021-05-17 | Eingeleitet | JP Morgan | Overweight |
| 2021-05-17 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-05-17 | Eingeleitet | SVB Leerink | Outperform |
| 2021-05-17 | Eingeleitet | Wells Fargo | Overweight |
Alle ansehen
Neuropace Inc Aktie (NPCE) Neueste Nachrichten
JP Morgan Raises Price Target for NPCE to $20.00, Maintains Over - GuruFocus
JPMorgan Chase & Co. Issues Positive Forecast for NeuroPace (NASDAQ:NPCE) Stock Price - MarketBeat
NeuroPace stock rises on positive NAUTILUS trial results, UBS reiterates Buy - Investing.com UK
NeuroPace Announces Positive 18-Month NAUTILUS Trial Results in Idiopathic Generalized Epilepsy - BioSpace
Neuropace shows 77% reduction in seizures - BioWorld MedTech
NeuroPace presents NAUTILUS trial data at American Epilepsy Society meeting - TipRanks
NeuroPace reports 77% seizure reduction in epilepsy device trial - Investing.com
NeuroPace reports 77% seizure reduction in epilepsy device trial By Investing.com - Investing.com Canada
Neuropace announces positive 18-month NAUTILUS trial results in idiopathic generalized epilepsy - marketscreener.com
NeuroPace, Inc. $NPCE Shares Acquired by Divisadero Street Capital Management LP - MarketBeat
Is NeuroPace Stock Built to Withstand a Pullback? - Trefis
MACD Signal: Will USCF ETF Trust USCF Sustainable stock attract long term capital inflowsJuly 2025 Analyst Calls & Reliable Intraday Trade Plans - BỘ NỘI VỤ
NeuroPace Stock Jump Looks Great, But How Secure Is That Gain? - Trefis
Panagora Asset Management Inc. Makes New $1.11 Million Investment in NeuroPace, Inc. $NPCE - MarketBeat
Will NeuroPace Inc. stock deliver consistent dividendsEarnings Growth Summary & Reliable Price Breakout Signals - Newser
Published on: 2025-12-04 13:47:14 - Newser
Is NeuroPace Inc. stock ready for breakoutJuly 2025 Summary & Free Long-Term Investment Growth Plans - Newser
Baird Medical Appoints Mark Saxton as U.S. CEO; Taps Veteran from NeuroPace, Smith + Nephew, and Covidien to Lead Commercial Expansion - marketscreener.com
NeuroPace to Highlight Life-Changing Outcomes and AI-Powered Confident Care at the 2025 American Epilepsy Society (AES) Annual Meeting - BioSpace
NeuroPace to Highlight Life-Changing Outcomes and AI-Powered Confident Care at the 2025 American Epilepsy Society Annual Meeting - Investing News Network
Why analysts remain bullish on NeuroPace Inc. stockM&A Rumor & Technical Entry and Exit Alerts - Newser
NeuroPace (NASDAQ:NPCE) Trading Down 4.1%Should You Sell? - MarketBeat
NeuroPace announces Medicare reimbursement increases for RNS System - MSN
NeuroPace, Inc. (NASDAQ:NPCE) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Why NeuroPace, Inc. (NASDAQ:NPCE) Could Be Worth Watching - 富途牛牛
NeuroPace, Inc. (NPCE) Reports Q3 Loss, Tops Revenue Estimates - MSN
NeuroPace NPCE insider updates holdings after RSU tax withholding - Stock Titan
Medicare boosts reimbursement for NeuroPace’s epilepsy treatment system By Investing.com - Investing.com South Africa
NeuroPace Announces Favorable Medicare Reimbursement Increases for RNS System Physician and Hospital Outpatient Services - Investing News Network
Medicare boosts reimbursement for NeuroPace’s epilepsy treatment system - Investing.com
NeuroPace jumps as Medicare boosts pay for epilepsy device procedures - TradingView
NeuroPace Says Medicare Increases Reimbursement for RNS Procedures - marketscreener.com
NeuroPace Inc Stock Analysis and ForecastVolatility Index Analysis & Access High Yield Alerts - earlytimes.in
Can NeuroPace Inc. stock deliver strong Q4 earningsMarket Growth Summary & Real-Time Sentiment Analysis - newser.com
Is NeuroPace Inc. stock gaining market shareBond Market & Consistent Profit Trade Alerts - newser.com
Why NeuroPace Inc. stock could rally in 2025July 2025 Chart Watch & Free Weekly Chart Analysis and Trade Guides - newser.com
Why NeuroPace Inc. stock remains on buy listsMarket Risk Analysis & AI Driven Price Predictions - newser.com
3 Stocks Possibly Trading At A Discount Of Up To 37.8% - Sahm
How rising interest rates impact NeuroPace Inc. stockTrade Signal Summary & Real-Time Stock Price Movement Reports - newser.com
NeuroPace, Inc. Reports Record Revenue and Strong Margins in Q2 2025 Earnings Call - MSN
Neuropace, Inc. Advances in Treating Lennox-Gastaut Syndrome: A Study Update - MSN
How to escape a deep drawdown in NeuroPace Inc.Global Markets & Daily Chart Pattern Signal Reports - newser.com
Revenues Tell The Story For NeuroPace, Inc. (NASDAQ:NPCE) As Its Stock Soars 25% - simplywall.st
Finanzdaten der Neuropace Inc-Aktie (NPCE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.34%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):